Slide 1: Recursion Learnings Call
o- Recursion Learnings) Call
Slide 2: Forward-looking statements
This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and pr
Slide 3: Recursion Poised to Hit TechBio Escape Velocity: Pipeline, Platform, and People
Recursion Poised to Hit TechBio Escape Velocity Pipeline, Platform, and People 3
Slide 4: Pipeline
Pipeline e Recursion.
Slide 5: More than a dozen discovery and research programs in oncology or with our partners
5 More than a dozen discovery and research programs in oncology or with our partners – first program optioned by Roche-Genentech in GI-oncology All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK. (1) Prevalence for h
Slide 6: Platform
Platform e Recursion.
Slide 7: Access to hundreds of thousands of de-identified records, including Helix's Exome+
7 Access to hundreds of thousands of de-identified records, including Helix’s Exome+(R) genomics & longitudinal health data, to train causal AI models and design biomarker & patient stratification strategies across broad disease areas
Slide 8: We just announced that we have sequenced our millionth transcriptome
We just announced that we have sequenced our 1 MILLIONTH transcriptome In the process of creating a full genome transcriptomic map to explore novel biology and complement our phenotypic maps 8
Slide 9: Active Learning Experiments
Kn ow le dg e Experiments Source: https://openreview.net/forum?id=u6HN2jC6gU Active Learning Experiments Randomized Experiments
Slide 10: BioHive-2: 23.32 petaflops
BioHive-2: 23.32 petaflops Completed in ~3 weeks 10 Top500 List from Nov 2023
Slide 11: People
People e Recursion.
Slide 12: Najat Khan, PhD, Appointed Chief R&D Officer & Chief Commercial Officer and Board Member
Najat Khan, PhD, Appointed Chief R&D Officer & Chief Commercial Officer and Board Member • Former Chief Data Science Officer and Co- Chair of Data Science Council at Johnson & Johnson Michael Bronstein, DeepMind Professor of Artificial Intelligence, Oxford • Appointed as Recursion/Valence advisor Re
Slide 13: Guidance
Guidance e Recursion.
Slide 14: Pipeline, partners and platform guidance; ~$296M cash
Pipeline: • Five expected Ph2 readouts in the next 18 months • Additional Ph2 trial starts in 2024 • Potential for additional INDs Partners: • Roche and Genentech: Pioneering collaboration, potential near-term program & map options • Bayer: Significant deal value, focused on undruggable oncology, po
Slide 15: Questions?
Learnings) Call Questions?